SK-01 (Acıbadem Labcell)

SK-01 is an experimental candidate developed by Acibadem Labcell for the prevention or treatment of COVID-19. It is designed to target the SARS-CoV-2 spike (S) protein, which is the primary mechanism the virus uses to attach to and enter human cells via the ACE2 receptor. Developed by the Turkish cell laboratory Acibadem Labcell, the project is part of a broader portfolio of COVID-19 related research that includes other candidates like OZG-3861. While the specific modality (such as a protein subunit vaccine or a cell-based therapy) has not been explicitly detailed in public pipeline summaries, it is categorized as an immunotherapy or vaccine candidate targeting the viral spike protein. As of the latest available data, its development status is listed as pending or in the early stages of evaluation.

Other names

SK-01-Acibadem Labcell-SARS-CoV-2 S protein-COVID-19SK01-Acibadem Labcell-SARS-CoV-2 S protein-COVID-19SK 01-Acibadem Labcell-SARS-CoV-2 S protein-COVID-19